Overall, with the synthesis of conjugates of betulin/BA, a linker, and CA IX inhibitor fragments, the dual strategy to produce effective therapeutics that can inhibit tumor-associated hCA IX has been successfully implemented in in vitro tumor models. The gene discussed is CA9; the disease is neoplasm.